Loading clinical trials...
Loading clinical trials...
A Descriptive Pharmaco-epidemiological Study of a Hypertensive Patient Population Treated With a Fixed-dose Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg and of Conditions for the Management of Arterial Hypertension
Conditions
Locations
915
France
Boehringer Ingelheim Investigator site 1
Ablon-sur-Seine, France
Boehringer Ingelheim Investigator site 2
Achenheim, France
Boehringer Ingelheim Investigator site 3
Afa, France
Boehringer Ingelheim Investigator site 4
Aiguillon, France
Boehringer Ingelheim Investigator site 5
Aire-sur-l'Adour, France
Boehringer Ingelheim Investigator site 6
Aix-en-Othe, France
Start Date
May 1, 2009
Primary Completion Date
November 1, 2009
Last Updated
June 5, 2014
NCT02417740
NCT07480265
NCT07073820
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions